Britain approves Valneva's easy-to-store COVID shot
Send a link to a friend
[April 14, 2022]
(Reuters) -Britain approved on
Thursday Valneva's COVID-19 vaccine, making it the first European
country to give a nod to the French firm's coronavirus shot, that is
easier to store and involves a process widely used in making flu and
polio vaccines.
The shot is also the sixth COVID-19 vaccine to be approved in the UK,
whose government had in September scrapped a 1.4 billion euro supply
deal.
Euronext temporarily halted trading in Valneva's shares, that were
indicated sharply up. At Wednesday's closing price of 15.255 euros, they
are down 37.7% since the start of year after gaining 216% in 2021 and
202% in 2020
"It is also the first, whole-virus inactivated COVID-19 vaccine to gain
regulatory approval in the UK," the UK health watchdog said in a
statement, adding the shot met required safety, quality and
effectiveness standards.
In vaccines such as Valneva's VLA2001, the virus is grown in a lab and
then made completely inactive so that it cannot infect cells or
replicate in the body but can still trigger an immune response. It is
seen by some as having the potential to win over people wary of some
which use new mRNA technology.
Rx Securities' managing director Samir Devani said even after the mass
roll-out, Valneva's vaccine could still be useful if a new variant
arises.
"The fact that it is available on hand is good news, although the exact
revenue profile beyond the orders already received from the EU and
Bahrain remains unclear," he said.
Devani said the approval bodes well for the decision from the EU's human
medicines committee (CHMP), which is assessing the drug after the
European Commission signed an advance deal for up to 60 million doses.
[to top of second column]
|
A biologist at the French-Austrian biotech firm Valneva works on an
inactivated whole-virus vaccine against coronavirus disease
(COVID-19) in a laboratory in Vienna, Austria, December 16, 2021.
REUTERS/Lisi Niesner
Valneva has said in March it
expected a positive EMA recommendation this month and that it had
begun manufacturing and has inventory ready for labelling and
deployment once it is is approved there.
Bahrain granted Valneva's vaccine emergency use authorisation in
early March.
Earlier this year, analysts at Jefferies estimated 4 to 5.5 billion
COVID-19 vaccine doses will be delivered globally this year, mostly
outside the European Union and United States, which have received
the lion's share of supplies.
VLA2001's storage temperature is similar to that of a domestic
refrigerator, making it appropriate in countries where storage at
very low temperatures is a challenge.
(Reporting by Aby Jose Koilparambil in Bengaluru, Benoit Van
Overstraeten and Sarah Morland; editing by Uttaresh.V)
[© 2022 Thomson Reuters. All rights
reserved.] This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|